👇
24 weight-loss drugs, ranked by how much weight people lost compared with placebo.
Retatrutide is #1 at 22%.
29
House of Peptides retweeted
🚨BREAKING: Eli Lilly just broke ground on a $3.5 billion factory in Pennsylvania that will make Retatrutide, its triple-agonist weight loss shot, even though it's still in Phase 3 and not approved yet.
House of Peptides retweeted
Copper peptide PAIRED with hyaluronic acid supercharged collagen IV by 25x in human skin cells. Incredible.
Copper peptide + HA ftw!
House of Peptides retweeted
Lifting weights 3x a week while taking a GLP-1 preserved muscle, had double digit strength gains, and got rid of fat.
Lifting + GLP-1s FTW.
House of Peptides retweeted
glucagon is literally why reta burns more than tirz. calling it the weak link is crazy work. lift and eat your protein either way
THE GREAT RETA LIE
What if retatrutide’s third receptor is actually a disadvantage for people who want to lose fat and preserve muscle?
Everyone is celebrating that retatrutide activates THREE receptors instead of two.
But that third receptor is glucagon.
A catabolic hormone.
Glucagon signaling can increase energy expenditure, potentially allowing you to burn more calories per day (to the tune of 70-250).
Not bad.
But HOW does it increase energy expenditure?
One of glucagon’s well-established actions is increasing amino acid uptake and breakdown in the liver.
Essentially, you’re increasing amino acid catabolism.
Why in God’s green earth would you WANT to increase amino acid breakdown when your entire goal is to lose fat and preserve muscle?
“But I’ll just eat more protein!”
Okay. But now you’re eating more calories to compensate for the increased amino acid oxidation.
You’re offsetting the additional calories you were trying to burn.
Wouldn’t it be better to avoid unnecessarily increasing amino acid catabolism in the first place?
And that’s before considering retatrutide significantly increases resting heart rate.
But what does the actual body composition data say?
In separate phase 2/body composition analyses, approximately 37% of weight lost with retatrutide has been cited as lean mass, compared with roughly 25% in the tirzepatide SURMOUNT-1 substudy.
That’s a substantial difference.
It raises an important question: Is most of retatrutide’s additional weight loss coming at the expense of lean tissue?
I think so.
This is why I’ve favored tirzepatide for my fat-loss and body-composition goals and for my clients.
And why I personally use 2.5 mg of tirzepatide per week.
House of Peptides retweeted
GHK Isn't Just Repairing Tissue. Russian Researchers Are Investigating Its Effects on the Brain.
And the research is getting increasingly interesting.
Between 2025 and 2026, researchers at Kursk State Medical University and the Kurchatov Institute published experiments investigating how modifying GHK’s three-amino-acid structure changes its biological activity.
Here’s what they’ve found:
1. Anxiety
GHK-GP (Gly-His-Lys-Gly-Pro) demonstrated anxiolytic-like effects at 0.5 and 5 μg/kg in the elevated-plus-maze model.
2. Pain
GHK-PGP (Gly-His-Lys-Pro-Gly-Pro) demonstrated analgesic-like activity at all three tested doses in the hot-plate test.
It also affected the tail-flick response, something neither parent peptide significantly achieved in that experiment.
3. Depression-related behavior
In a 2026 study involving 200 rats:
• GHK-PGP showed antidepressant-like activity at 5 μg/kg.
• GHK-VEP showed activity at just 0.5 μg/kg.
• GHK-GP showed no significant effect at any tested dose.
Now consider what this means.
Researchers started with the same three amino acids: Gly-His-Lys.
By modifying the C-terminal sequence, they produced peptides with different activity profiles across multiple behavioral models.
The original objective was to explore protection against enzymatic degradation.
But the findings raise a much bigger question.
Can terminal amino-acid modifications redirect the pharmacology of an existing peptide?
This is closely aligned with the Russian peptide-development philosophy behind compounds like Semax and Selank.
Important distinction: these were animal studies of GHK derivatives, not copper-bound GHK-Cu. The mechanisms, pharmacokinetics and human efficacy remain unestablished.
But the broader discovery opportunity is obvious.
GHK may not be one therapeutic candidate. It may be the starting scaffold for an entire family of them.
And we’re only beginning to examine the untranslated research.
Research: molekul.io
One Extra Amino Acid Made GHK 5× More Effective at Wound Healing
Russian researchers added ONE amino acid to GHK. Wound healing accelerated up to 5.3×.
And that’s not even the most interesting finding.
In a 2024 study from Kursk State Medical University, researchers tested 3 peptides in an infected-wound model involving 150 rats:
• GHK: Gly-His-Lys
• D-Ala-GHK: D-alanine added to the beginning
• GHK-D-Ala: D-alanine added to the end
Same building blocks. Different placement. Dramatically different results.
GHK-D-Ala stood out:
• 4.7–5.3× faster wound healing during days 7–10 versus controls
• 93% smaller wound area by day 10 at the lower tested dose versus controls
• 37% lower bacterial contamination at that dose
• Earlier granulation, wound cleansing, and epithelialization
Here’s the fascinating part.
Adding D-alanine to the C-terminus may protect GHK from enzymatic degradation, allowing its regenerative activity to persist longer.
Move that same amino acid to the opposite end and the results change.
The parent GHK peptide actually performed better at some earlier timepoints, making the timing of these effects especially interesting.
This is the Soviet/Russian peptide-engineering philosophy in action: modify a small peptide’s structure to change its biological behavior.
The researchers even proposed investigating a copper-complexed GHK-D-Ala nanoparticle formulation.
That formulation remains a research proposal, not an established treatment.
GHK-Cu may be just the beginning.
House of Peptides retweeted
Did retatrutide just TRIPLE heart attacks?! 🚨
In its latest Phase 3 trial, 9 people on Reta suffered a heart attack or stroke vs. just 1 on placebo.
Sounds terrifying, right?
But there's a HUGE catch in the data.
And another trial showed the exact OPPOSITE.
So is Reta actually dangerous for your heart, or are people reading the numbers wrong?
Let's break it down. 🧪



























